Searching for the ideal LDL cholesterol estimating formula

For long, low-density lipoprotein cholesterol (LDL-C) has been considered one of the major therapeutic targets for primary and secondary prevention in cardiovascular (CV) disease. Since more than two decades ago, pivotal trials have demonstrated that LDL-C lowering with statins translates into a log proportional reduction in a vast array of CV events (myocardial infarction, stroke, need for coronary or arterial revascularization), as well as mortality [1]. More recently, similar benefits have been observed with other LDL-C lowering therapies, such as ezetimibe [2] and proprotein covertase subtilisin kexin type 9 (PCSK-9) inhibitors [3].

Source: International Journal of Cardiology - March 9, 2021 Category: Cardiology Authors: Remo Holanda de Mendonca Furtado Tags: Editorial Source Type: research